AbbVie Exercises its Option to License Morphosys’ αvβ6 Integrin Inhibitor Program for Fibrotic Disease

 AbbVie Exercises its Option to License Morphosys’ αvβ6 Integrin Inhibitor Program for Fibrotic Disease

AbbVie Exercises its Option to License Morphosys’ αvβ6 Integrin Inhibitor Program for Fibrotic Disease

Shots:

  • Morphic will receive a $20M as license fee and is eligible to receive milestones and royalties on sales of any commercialized therapy while AbbVie has exercised a license option under the companies’ R&D collaboration agreement to develop Morphic’s αvβ6 integrin inhibitors for fibrotic diseases including IPF and additional indications
  • The license covers αvβ6 integrin inhibitors including MORF-720 and MORF-627, supported by an extensive preclinical data demonstrating potential as treatments for IPF as well as other fibrotic diseases
  • Under the original deal, Morphic would handle R&D work on its pipeline through IND-enabling studies, after which AbbVie has an option to take each compound for global development and commercialization

Click here ­to­ read full press release/ article | Ref: AbbVie | Image: WSJ

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post